|
Q2 FY2026
As of Jun 27, 2026
|
Q1 FY2026
As of Mar 28, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 27, 2025
|
Q2 FY2025
As of Jun 28, 2025
|
Q1 FY2025
As of Mar 29, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 28, 2024
|
Q2 FY2024
As of Jun 29, 2024
|
Q1 FY2024
As of Mar 30, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jul 1, 2023
|
Q1 FY2023
As of Apr 1, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Oct 1, 2022
|
Q2 FY2022
As of Jul 2, 2022
|
Q1 FY2022
As of Apr 2, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Oct 2, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable, less allowances of $148 and $147 | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Contract assets, net | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Acquisition-related intangible assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities, redeemable noncontrolling interest and equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Short-term obligations and current maturities of long-term obligations | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued payroll and employee benefits | ||||||||||||||||||||
| Contract liabilities | ||||||||||||||||||||
| Other accrued expenses | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Long-term obligations | ||||||||||||||||||||
| Redeemable noncontrolling interest | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Thermo Fisher Scientific Inc. shareholders’ equity: | ||||||||||||||||||||
| Preferred stock, $100 par value, 50,000 shares authorized; none issued | ||||||||||||||||||||
| Common stock, $1 par value, 1,200,000,000 shares authorized; 445,673,899 and 445,160,301 shares issued | ||||||||||||||||||||
| Capital in excess of par value | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock at cost, 75,926,613 and 68,938,831 shares | ||||||||||||||||||||
| Accumulated other comprehensive income/(loss) | ||||||||||||||||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities, redeemable noncontrolling interest and equity |
Loading...
